Effects of pegylated interferon‐α based therapies on functional cure and the risk of hepatocellular carcinoma development in patients with chronic hepatitis B

2019 ◽  
Vol 26 (S1) ◽  
pp. 5-31 ◽  
Author(s):  
Hong Ren ◽  
Yan Huang
Keyword(s):  
Hepatocellular Carcinoma ◽  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Pegylated Interferon ◽  
Interferon Α ◽  
Functional Cure

Hepatitis B core-related antigen levels predict pegylated interferon-α therapy response in HBeAg-positive chronic hepatitis B

2020 ◽  
Author(s):  
Boris JB Beudeker ◽  
Zwier MA Groothuismink ◽  
Robert A de Man ◽  
Harry LA Janssen ◽  
Annemiek A van der Eijk ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Therapy Response ◽  
Pegylated Interferon ◽  
Interferon Α ◽  
Positive Chronic Hepatitis

Efficacy and tolerability of pegylated interferon-α-2a in chronic hepatitis B: A multicenter clinical experience

2012 ◽  
Vol 27 (9) ◽  
pp. 1447-1453 ◽  
Author(s):  
Dilip Ratnam ◽  
Anouk Dev ◽  
Tin Nguyen ◽  
Vijaya Sundararajan ◽  
Hugh Harley ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Clinical Experience ◽  
Pegylated Interferon ◽  
Interferon Α

scholarly journals Sequential therapy involving an early switch from entecavir to pegylated interferon-α in Japanese patients with chronic hepatitis B

2018 ◽  
Vol 48 (6) ◽  
pp. 459-468 ◽  
Author(s):  
Masaru Enomoto ◽  
Shuhei Nishiguchi ◽  
Akihiro Tamori ◽  
Ritsuzo Kozuka ◽  
Hideki Fujii ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Sequential Therapy ◽  
Japanese Patients ◽  
Pegylated Interferon ◽  
Interferon Α

scholarly journals Liver Histopathological Features Influencing HBeAg Seroconversion in Patients with HBeAg-positive Chronic Hepatitis B Treated with Pegylated Interferon α

2014 ◽  
Vol 3 (1) ◽  
pp. 10-15
Author(s):  
Yao-ren Hu ◽  
Hua-dong Yan ◽  
Guo-sheng Gao ◽  
Cheng-liang Zhu ◽  
Ji-fang Cheng
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Hbeag Seroconversion ◽  
Pegylated Interferon ◽  
Interferon Α ◽  
Binary Logistic Regression Analysis ◽  
Liver Inflammation ◽  
Histopathological Features ◽  
Positive Chronic Hepatitis

Abstract Objective To investigate the efficiency of pegylated interferon α therapy for patients with HBeAg-positive chronic hepatitis B (CHB) and explore whether liver histopathological features and other factors might influence HBeAg seroconversion. Methods Total of 80 HBeAg-positive CHB patients who received liver puncture were treated with pegylated interferon α once a week for 48 weeks. The rate of HBeAg seroconversion was determined after therapy, and the factors influencing HBeAg seroconversion were analyzed. Results The rate of HBeAg seroconversion was 30.00％ at the end of treatment. The rate of HBeAg seroconversion gradually increased with the elevation of liver inflammatory activity (χ2 = 9.170, P = 0.027). But liver fibrosis has little correlation with the rate of HBeAg seroconversion (χ2 = 5.917, P = 0.116). Except HBeAg, other baseline indexes including gender, age, serum ALT and serum HBV DNA 1evels had no statistical difference between the patients with HBeAg seroconversion and the patients without HBeAg seroconversion. By binary logistic regression analysis, liver inflammation and HBeAg were influencing factors for HBeAg seroconversion. Conclusions Pegylated interferon α therapy induces a higher rate of HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients with severe liver inflammation, so the liver biopsies should be performed in time.

Sign in / Sign up

Export Citation Format

Share Document